Immunization of Patients with Malignant Melanoma with Autologous CD34 <sup>+</sup> Cell-Derived Dendritic Cells Transduced <i>Ex Vivo</i> with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial

Massimo Di Nicola(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro M. Gianni(University of Milan), Daniele Morelli(Fondazione IRCCS Istituto Nazionale dei Tumori), Gerd Sutter(Department of Virology), Ingo Drexler(Düsseldorf University Hospital), Gianfrancesco Gallino(Colon and Rectal Surgery Associates), Nathaly Arndtz(Bavarian Nordic (Germany)), Carmelo Carlo‐Stella(Humanitas University), Giorgio Parmiani(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberta Mortarini(Scripps Research Institute), Anna Guidetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Gabrina Tragni(Tumori Foundation), Paul Chaplin(Bavarian Nordic (United States)), Fernando Ravagnani(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Natale Cascinelli, Andrea Anichini(Fondazione IRCCS Istituto Nazionale dei Tumori)
Human Gene Therapy
September 11, 2003
10.1089/104303403322319426
Cited by 21

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2015|740
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606